STO · BICO.ST
BICO Group AB (publ)
SEK 24.45+SEK 0.30 (+1.24%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 3.82% below the high.
Loading market information…
OTC · CFOR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CapForce Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CapForce Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$48.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CapForce Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CapForce Inc. is a precision medicine company dedicated to developing and commercializing sophisticated molecular microbiology solutions. Its mission is to address life-threatening infectious diseases for patients in the United States and across international markets. The company's diverse product range includes Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel diagnostic tests, and SARS CoV-2 testing kits. Beyond its product line, CapForce extends its offerings to include laboratory services, collaboration services (such as funded software arrangements), and licensing agreements. Additionally, the company provides listing sponsorship and consultancy services. Formerly known as OpGen, Inc., the entity officially changed its name to CapForce Inc. in February 2026. CapForce Inc. was established in 2001 and maintains its headquarters in Clarksburg, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 15, 2024 | $1.35+184.38% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q2 2024 | Aug 19, 2024 | -$1.18+30.59% vs estimate | $28.00K-98.13% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 24.45+SEK 0.30 (+1.24%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 3.82% below the high.
$3.72-$0.12 (-3.13%)
Anbio Biotechnology Class A Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 91.68% below the high.
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
$19.35+$0.67 (+3.59%)
Precipio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
$5.72+$0.77 (+15.56%)
Interpace Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.33% below the high.
$1.74-$0.01 (-0.57%)
Biomerica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.82% below the high.
$1.83+$0.16 (+9.58%)
Intelligent Bio Solutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.65% below the high.
